Prime Medicine Inc (PRME)
7.085
+0.04
(+0.64%)
USD |
NASDAQ |
May 17, 16:00
7.085
0.00 (0.00%)
Pre-Market: 20:00
Prime Medicine Cash from Operations (TTM): -191.56M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -191.56M |
| December 31, 2023 | -165.41M |
| September 30, 2023 | -152.26M |
| Date | Value |
|---|---|
| June 30, 2023 | -143.19M |
| March 31, 2023 | -122.60M |
| December 31, 2022 | -131.83M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-191.56M
Minimum
Mar 2024
-122.60M
Maximum
Mar 2023
-151.14M
Average
-147.73M
Median
Cash from Operations (TTM) Benchmarks
| Pacific Biosciences of California Inc | -240.16M |
| 10x Genomics Inc | -26.80M |
| Recursion Pharmaceuticals Inc | -316.76M |
| Verve Therapeutics Inc | -143.54M |
| Ginkgo Bioworks Holdings Inc | -294.17M |